The SMO Group announces company name change to Oximio - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

The SMO Group announces company name change to Oximio

19 Apr 2021

Sponsored by Oximio Sponsored by Visit Company
The SMO Group announces company name change to Oximio

The global clinical trial services provider The SMO Group announced earlier this year that the company will begin operating under a new name and will be known henceforth as Oximio, effective immediately. The 18-month extensive rebranding project is a response to the accelerated company growth and a renewal of the company vision.

“By announcing Oximio, we are opening the next chapter in the company’s history. In the past 16 years we have grown to become a truly global company, constantly focusing on further geographical expansion and strengthening our service portfolio. In the past years we put a huge effort into developing a quality led organization, which has resulted in higher patient satisfaction and a wider service coverage.

“I believe it was appropriate to rebrand our company to better reflect the fresh and professional mindset of our people and to emphasize the knowledge, expertise and added value we bring to the clinical research market.” – CEO, Krisztina Varga stated. “The new brand will help us seize the opportunity to reinforce our reputation of being a well-established clinical trials services provider, building on our history and our strong company culture. We aim to provide a full brand experience to our clients to help them be more successful in their core business.

We will be working extremely hard to achieve our vision: We are dedicated to expediting research to find effective treatments and cures for all living beings.”

The company’s ownership, staff, and legal entity names remain unchanged. Both names – SMO GROUP® and OXIMIO®, as our registered trademarks will be used within a transition period and thereafter on per case basis.

For more information about the brand change, please visit our new website: oximio.com.

Free Whitepaper

Regional Focus: In the Front Lines of Clinical Trials

Oximio is a well-established clinical trials service provider that helps researchers around the world discover effective treatments and cures for medical needs. With a global presence spanning regions such as the UK, Eastern Europe, Western Asia, and South Africa, Oximio harnesses a deep understanding of a range of international clinical trial markets. Focusing on its Eastern European operations, this whitepaper provides an overview of the Russian, Georgian and Ukranian clinical trial landscape, including discussions of the unique advantages and opportunities that each market presents.

The whitepaper explores the local regulations and legislation that govern clinical research in these markets, as well as the steps and processes that researchers must take to secure approval and register drugs there. The key services provided by Oximio to support clinical trials in these countries are also detailed, including fact sheets on the service provider’s local depots, capacities and operational timelines.

By clicking the “Submit” button above, you accept and acknowledge that your data will be used as described in the Oximio Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.